Cargando…
Amantadine for COVID-19 treatment (ACT study): a randomized, double-blinded, placebo-controlled clinical trial
OBJECTIVES: The COVID-19 pandemic has revealed a severe need for effective antiviral treatment. The objectives of this study were to assess if preemptive treatment with amantadine for COVID-19 in non-hospitalized persons ≥40 years or adults with comorbidities was able to prevent disease progression...
Autores principales: | Weis, Nina, Bollerup, Signe, Sund, Jon Dissing, Glamann, Jakob Borg, Vinten, Caroline, Jensen, Louise Riger, Sejling, Christoffer, Kledal, Thomas Nitschke, Rosenkilde, Mette Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284620/ https://www.ncbi.nlm.nih.gov/pubmed/37353078 http://dx.doi.org/10.1016/j.cmi.2023.06.023 |
Ejemplares similares
-
Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro
por: Toft-Bertelsen, Trine Lisberg, et al.
Publicado: (2021) -
Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro
por: Toft-Bertelsen, Trine Lisberg, et al.
Publicado: (2021) -
Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1
por: Knerr, Julius Maximilian, et al.
Publicado: (2021) -
Reply to: How Many SARS-CoV-2 “Viroporins” Are Really Ion Channels?
por: Toft-Bertelsen, Trine L., et al.
Publicado: (2022) -
Publisher Correction: Reply to: How many SARS-CoV-2 “viroporins” are really ion channels?
por: Toft-Bertelsen, Trine L., et al.
Publicado: (2022)